Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...

Camcevi ETM contains 21mg of leuprolide and is administered every 3 months. The Food and Drug Administration (FDA) has approved Camcevi ETM ®, a long-acting formulation of leuprolide mesylate, for the ...

The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...

The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse ...

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...

Prostate cancer diagnoses increased by 3% per year from 2014 to 2021, with the sharpest increase seen in advanced-stage disease. Prostate cancer mortality rates have continued to decline, but at a ...

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme Dr Kenrick Ng, Medical Oncology Consultant, St Bartholomew's Hospital, ...